Scholars Central

Conference abstractPublished 31 Dec 2020

Update on gene therapy and other treatment modalities for adenosine deaminase deficiency

Authors: Dr. Daifulah ALZahrani

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Adenosine deaminase (ADA) deficiency is one of the primary immunodeficiency diseases, that affects the immune system through accumulated metabolites of purine metabolism. It is an autosomal-recessive disorder with an estimated incidence around 0.5 per 100,000 live births. Patients with severe form usually present in infancy where the accumulation of the toxic metabolites; deoxyadenosine and deoxyadenosine triphosphate (dAXP), causing defective differentiation and function of immune cells; T, B, and natural killer (NK) leading to severe combined immunodeficiny.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Next Generation Sequencing & Applications.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Next Generation Sequencing & Applications
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Dr. Daifulah ALZahrani”